Książki

Antibody-drug conjugates are a promising areas of anticancer drug discovery, conveying several advantages, including the ability to select likely responders, efficient delivery of cytotoxic agents and reduced toxicity. This book describes payloads used to date and novel payloads that may be used clinically in the future.

Cytotoxic Payloads for Antibody-Drug Conjugates

Introduction to Antibody-Drug Conjugates (ADCs); Design Factors Important for Antibody-Drug Conjugate (ADC) Payloads; Use of Molecular Modelling Techniques in Antibody-Drug Conjugate (ADC) Payload Discovery and Development; Auristatin Payloads for Antibody-Drug Conjugates (ADCs); Maytansinoid Payloads for Antibody-Drug Conjugates (ADCs); Colchicine-, Vinblastine-, Taxol- and Eribulin-based Payloads for Antibody-Drug Conjugates (ADCs); Traditional Cytotoxic Agents as Antibody-Drug Conjugate (ADC) Payloads; Topoisomerase Inhibitors as Antibody-Drug Conjugate (ADC) Payloads; Duocarmycins as Antibody-Drug Conjugate (ADC) Payloads; CXI Dimers as Antibody-Drug Conjugate (ADC) Payloads; Duocarmycin-PBD Dimers as Antibody-Drug Conjugate (ADC) Payloads; Calicheamicins as Antibody-Drug Conjugate (ADC) Payloads; Pro-pyrrolobenzodiazepines and Conjugates as Antibody-Drug Conjugate (ADC) Payloads; Pyrrolobenzodiazepine Dimers as Antibody-Drug Conjugate (ADC) Payloads; Indolinobenzodiazepine Dimers (IGNs) as Antibody-Drug Conjugate (ADC) Payloads; Pyridinobenzodiazepines (PDDs) as Sequence-selective DNA Mono-alkylating Antibody-Drug Conjugate (ADC) Payloads; Splicing Inhibitors as Antibody-Drug Conjugate (ADC) Payloads; Tubulysins as Antibody-Drug Conjugate (ADC) Payloads; Amatoxins as RNA Polymerase II Inhibiting Antibody-Drug Conjugate (ADC) Payloads; Protein Toxins as Antibody-Drug Conjugate (ADC) Payloads; Occupational Health and Safety Considerations for the Handling and Manufacture of Antibody-Drug Conjugate (ADC) Payloads; The Future of Antibody-Drug Conjugate (ADC) Payloads